Fri Sep 20 06:44:45 UTC 2024: ## MEI Pharma Receives “Buy” Rating from StockNews.com, but Mixed Sentiment Among Analysts

**Sep 20th, 2024** – MEI Pharma (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on cancer treatments, has received a “buy” rating from StockNews.com. However, the overall sentiment among analysts remains mixed.

While StockNews.com is bullish on MEI Pharma, other analysts have expressed more cautious views. Brookline Capital Management downgraded the stock from “strong-buy” to “hold” in July, followed by Laidlaw’s similar downgrade from “buy” to “hold.” Overall, three analysts have issued “hold” ratings and one has assigned a “buy” rating. MarketBeat.com currently gives MEI Pharma an average rating of “Hold” with an average price target of $7.00.

Despite the mixed analyst outlook, institutional investors remain interested in MEI Pharma. Cable Car Capital LLC recently acquired a new position in the company, acquiring 611,440 shares valued at $3,546,000. This makes MEI Pharma the 10th largest holding in Cable Car Capital LLC’s portfolio, representing approximately 3.9% of its total holdings.

MEI Pharma is currently developing two key therapies: Zandelisib, an oral drug for relapsed/refractory follicular lymphoma, and Voruciclib, an oral drug in Phase I clinical trials for acute myeloid leukemia and B-cell malignancies.

**To stay updated on the latest news and analyst ratings for MEI Pharma, sign up for MarketBeat.com’s free daily email newsletter.**

Read More